How ‘Magic Mushrooms’ Could Help Parkinson’s Disease Patients
A UCSF pilot study finds psilocybin therapy surprises, showing meaningful improvements in mood, cognition, and motor symptoms.
Psilocybin, a natural compound found in certain mushrooms, has shown promise in treating depression and anxiety.
UC San Francisco researchers wanted to know if it could be used to help Parkinson's patients who often experience debilitating mood dysfunction in addition to their motor symptoms and don’t respond well to antidepressants or other medications.
The results were surprising.
Not only did participants tolerate the drug without serious side effects or worsening symptoms, which is what the pilot study was designed to test, they also experienced clinically significant improvements in mood, cognition, and motor function that lasted for weeks after the drug was out of their systems.
It is the first time a psychedelic has been tested on patients with any neurodegenerative disease.
“We are still in very early stages of this work, but this first study went well beyond what we expected,” said the paper’s first author, Ellen Bradley, MD, assistant professor and associate director of UCSF’s Translational Psychedelic Research Program (TrPR).
“Many people don’t realize this, but mood symptoms in Parkinson’s are linked to a faster physical decline,” she said. “And they are actually a stronger predictor of patients’ quality of life with Parkinson's than their motor symptoms.”
Researchers in the TrPR Program, within UCSF’s Department of Psychiatry and Behavioral Sciences and the Department of Neurology, teamed up to lead this project, which was funded by an anonymous donor. The findings appeared online earlier this month in Neuropsychopharmacology, a Nature publication.
Psilocybin’s lasting mood and motor effects
Parkinson’s disease, a progressive neurodegenerative disorder characterized by uncontrolled movements due to abnormal brain activity, affects about 1 million Americans. While medications like levodopa can relieve symptoms, there are no approved therapies to slow the progression or reverse the disease itself.
Common early physical symptoms include tremors and foot dragging, but Bradley said anxiety and depression in patients with no history of psychiatric problems often precede the onset of motor symptoms by several years. It’s unclear why standard medications often don’t work well for these patients, but mood changes could be part of the neurodegenerative disease process.
To test the safety of psilocybin for these patients, the researchers gave seven men and five women with mild to moderate Parkinson’s disease a 10 mg dose, followed two weeks later by a higher dose of 25 mg. The patients completed psychotherapy sessions before and after the psilocybin — eight sessions in total — and were evaluated for changes in mood, cognition, and motor functions.
While nearly all participants experienced some adverse events while on the psilocybin, such as anxiety, nausea, and elevated blood pressure, these were not serious enough to require medical intervention.
The participants had meaningful improvements in their mood, cognition, and motor symptoms at both their one-week and one-month follow-up appointments. The team evaluated the participants’ mood again three months after their psilocybin sessions and found it was still significantly improved.
The researchers suggested a variety of explanations for the improvements. The beneficial impact of psilocybin on the patients’ mood could have led to better cognitive and motor functions. For example, people feel better, and that, in turn, helps them socialize and become more active – both key elements of Parkinson’s treatment.
Another theory is that psilocybin could provide relief from multiple symptoms of the disease by reducing inflammation and promoting neuroplasticity — the growth and reconnection of brain cells involved in mood, cognition, and movement regulation.
An expansion into unchartered territory
The results of this pilot study were promising enough that the researchers are conducting a larger randomized controlled trial at UCSF, enrolling a larger and more diverse group of patients. The second study incorporates noninvasive brain stimulation, neuroimaging and other tools to understand how psilocybin impacts inflammation and neuroplasticity.
It will include a second site at Yale University, with the aim of enrolling 100 participants. This work will be funded by the same anonymous donor that paid for the safety pilot as well as by the Michael J. Fox Foundation for Parkinson’s Research.
“The vast majority of brain diseases still lack interventions that change the course of illness,” said the study’s senior author, Joshua Woolley, MD, PhD, associate professor at UCSF and director of the TrPR Program. “We can often treat the symptoms, but we don’t alter the trajectory or prevent decline. Now, that’s beginning to change. These results raise the exciting possibility that psilocybin may help the brain repair itself.”
Authors: Additional co-authors include Kimberly Sakai, BA, Gisele Fernandes-Osterhold, MFT, Balázs Szigeti, PhD, Connie Ludwig, PhD, Jill L. Ostrem, MD, Caroline M. Tanner, MD, PhD, Meredith A. Block, MD, Katia Llerena, PhD, Patrick R. Finley, PharmD, Aoife O’Donovan, PhD, Jose Rafael P. Zuzuarregui, MD, Amber McKernan, BA, Andrew D. Penn, NP, Aliss C.C. Wang, MFT, and Raymond C. Rosen, PhD.
Funding: The trial was funded by an anonymous donor.
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu, or see our Fact Sheet.
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf
Journal
Neuropsychopharmacology